An integrated experimental and economic evaluation of cell therapy affinity purification technologies.

CONCLUSION: Technical and bioprocess benefits were noted with SpheriTech beads which, unlike FACS and MACS, require no cell labeling. This simplifies the bioprocess, reduces cell loss and leaves target cells label free. The economic tool predicted cost drivers and a critical dose (7 × 10(7) cells per dose) shifting the most cost-effective technology from FACS to MACS. Process optimization is required for SpheriTech to compete economically.
PMID: 28621179 [PubMed - as supplied by publisher]

Source: Regenerative Medicine - June 16, 2017 Category: Genetics & Stem Cells Authors: Weil BD, Jenkins MJ, Uddin S, Bracewell DG, Wellings D, Farid SS, Veraitch F Tags: Regen Med Source Type: research